ABSTRACT N-acetylcysteine (NAC) has been well studied in the treatment of acetaminophen-induced and select non-acetaminophen-induced liver failure. However, its role in the management of sickle cell hepatic crisis resulting in acute liver failure (ALF) is unknown. We describe and discuss the novel and beneficial use of NAC in a 25-year-old man with ALF due to sickle cell hepatic crisis. We further review ALF in sickle cell disease and NAC in the treatment of non-acetaminophen-induced liver failure. Our case highlights the promising role of NAC in sickle cell-related liver injury.
INTRODUCTION
Vaso-occlusive hepatic crises, which occur in roughly 10% of patients admitted with sickle cell disease (SCD) pain crisis, manifest with right upper quadrant abdominal pain, elevated levels of liver enzymes, and hyperbilirubinemia. 1 Acute liver failure (ALF) is a rare but fatal complication of vaso-occlusive hepatic crisis. Early exchange transfusions are used as an attempt to reverse this process.
2 N-acetylcysteine (NAC) in patients with SCD has shown promise in a randomized pilot study to reduce oxidative stress markers, central to the pathophysiology of sickle cell crises. 3 However, NAC is not routinely used for hepatic manifestations of SCD. Our case report focuses on the presentation and management of ALF in a patient with SCD as well as the evaluation of NAC as a novel supplemental therapy.
CASE REPORT
A 25-year-old man with SCD and frequent pain crises presented with altered mental status and right upper quadrant pain. On presentation, his laboratory test results were notable for hyperbilirubinemia .60 mg/dL, from a baseline of 20 mg/dL, an unreportable aspartate aminotransferase (due to an overly icteric sample), alanine aminotransferase 74 U/L, alkaline phosphatase 57 U/L, and an initial international normalized ratio of 3.2. He had a hemoglobin level of 8.5 g/dL with a hemoglobin S fraction of 54.2%. The patient's creatinine level was elevated at 3.4 mg/dL from the baseline 0.9 mg/dL. Serologic evaluation for alternate causes of liver disease including acute viral hepatitis was negative. Magnetic resonance imaging of the abdomen with contrast showed hemosiderosis of the liver (Figure 1) . No liver lesions, biliary ductal dilation, or hepatic vascular obstruction was present.
Exchange transfusion was performed on hospital day 1, given the known benefit of early exchange transfusion in vaso-occlusive crises. Despite a successful reduction of hemoglobin S burden to 14.9%, the patient remained encephalopathic and coagulopathic (international normalized ratio 1.9-2.3). After the persistent lack of improvement by day 5, the decision was made to try intravenous NAC. The infusion was given as an initial loading dose of 150 mg/kg over the first hour, then 50 mg/kg over 4 hours, and finally as a continuous infusion of 100 mg/kg over the remaining 16 hours. The patient subsequently became more alert and interactive. The patient had repeat sickling with hemoglobin S fraction of 30% requiring a second exchange transfusion on hospital day 13. He became clinically stable and was discharged from the hospital on day 17 (Table 1) .
DISCUSSION
ALF is a rare complication of vaso-occlusive crisis related to intrahepatic cholestasis in SCD and has been associated with a mortality of 40% in the absence of exchange transfusions. 2, 4, 5 To date, management has been limited: exchange transfusion is a first-line treatment followed by supportive therapy. 6 Exchange transfusion aims for rapid reduction of sickle cell fraction, ideally under 30%. This results in the reduction of viscosity associated with sickled cells and helps reverse the complications of acute anemia that would otherwise limit perfusion. Early exchange transfusion has been shown to reverse coagulopathy, reduce lactic acidosis, and improve hyperbilirubinemia in patients. 5, 7 In more isolated cases of SCD with ALF, transplant has been considered. Liver transplant in such patients is rare and risky, with over half of the patients suffering from complications including repeat vaso-occlusive crises, graft thrombosis, and infections. 8, 9 NAC can be considered in non-acetaminophen-induced (NAI) ALF per 2011 American Association for the Study of Liver Diseases guidelines and is recommended for use in 2017 European Association of the Liver guidelines.
10,11 NAC mitigates the detrimental effects of acetaminophen overdose through its ability to replete antioxidant glutathione stores and conjugate with N-acetyl-p-benzoquinone imine. 12 Furthermore, the antiinflammatory and antioxidant effects of NAC enhance oxygen delivery and perfusion. 13 NAC use in NAI ALF has been Figure 1 . In-phase T1-weighted magnetic resonance imaging demonstrating diffuse low signal and heterogeneity throughout the liver, consistent with hepatic hemosiderosis. The low signal in renal cortices is consistent with the additional iron deposition involving the kidneys. associated with mortality benefit and decreased hospital length of stay. 14 In a prospective, double-blinded study of 172 patients with NAI ALF (81 NAC; 92 placebo), a 72-hour infusion of intravenous NAC significantly improved transplant-free survival at 3 weeks (40% vs 27%). 15 Specifically, significant survival difference was noted in patients with hepatic coma scale I and II. However, the primary endpoint of overall survival was not significantly different between the groups. This case report illustrates the novel use of NAC in sickle cell hepatic crisis. While this specific context (SCD hepatic crisis) is novel, the rationale behind the use of NAC in SCD is supported in several studies. Oxidative stress plays an important role in SCD and derives from unstable hemoglobin S, chronic intravascular hemolysis, and repeat cycles of ischemia reperfusion injury. 3, 16 Mutated hemoglobin S causes damage to red blood cell membranes via polymer formation and auto-oxidation, generating iron-mediated oxidants. 17 Chronic, intermittent ischemiareperfusion injury and resultant reactive oxygen species induce endothelial damage, accelerating hemolysis and inflammatory vasculopathy. Consequently, sickle cell patients often have depleted stores of intrinsic antioxidants, such as amino-thiol glutathione. 18 As such, potential therapies have targeted the following measures: (i) increasing antioxidant activity; (ii) reducing endothelial adhesion activity; and/or (iii) reducing inflammation. NAC, by increasing antioxidant activity, has been studied as a potential therapy. A phase 2, double-blinded clinical trial of 21 patients with SCD showed that NAC, at a welltolerated dose of 2400 mg/d, inhibited dense cell formation, restored red blood cell glutathione levels, and reduced vasoocclusive crises (relative risk 0.39). 19 In a more recent, randomized pilot study of 11 patients with SCD , NAC at both 1,200 and 2400 mg/d similarly increased whole blood glutathione levels and decreased cell-free hemoglobin among other markers of oxidative vascular damage. 3 During the 6-week study period, none of the patients who received NAC experienced SCD crises. NAC, which is the rate-limiting substrate for generating glutathione, increases the amount of glutathione available to scavenge reactive oxygen species, reducing oxidative stress and downstream complications. Furthermore, NAC has been shown to potentiate nitric oxide, an endogenous vasodilator that enhances perfusion, reducing the sequelae of a prolonged hypoxic environment. 13 Despite promising results, existent SCD studies have limited patients and none evaluated the use of NAC in ALF related to SCD. Further studies are needed to better understand the use of NAC in sickle cell hepatic crises, such as in our patient. Given that management of SCD focuses conventionally on exchange transfusion, the clinical benefit of NAC in combination with exchange transfusion warrants investigation.
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